Complete Response to Trastuzumab and Pertuzumab in Combination with Chemotherapy in HER2-positive Metastatic Breast Cancer—Case Series—

Abstract

Purpose : The use of pertuzumab in combination with trastuzumab and chemotherapy may help achieve complete responses and improve the prognosis of HER2-positive metastatic breast cancer. Here we report cases of patients with HER2-positive metastatic breast cancer treated with the combination regimen.

Methods : Between March 2014 and August 2017, 93 patients were treated with trastuzumab and pertuzumab in combination with chemotherapy in the metastatic setting. We retrospectively collected the clinicopathological data of these patients.

Results : Of the 93 patients, 10 were assessed for clinical complete responses (cCR). Eight of these patients had been diagnosed with stage IV at first diagnosis, and 2, with recurrent cancer. Three patients underwent breast surgery after maintaining their cCR status, which resulted in pathological complete responses. Of the 7 patients who did not undergo breast surgery, 2 developed brain metastases.

Conclusions : Trastuzumab and pertuzumab in combination with chemotherapy might improve the rate of complete response in HER2-positive metastatic breast cancer patients.